Zimmer Biomet Holdings, Inc. (ZBH) - What Are Researchers Thinking About This Stock?

Key Points

• Analyst sentiment is mixed but leans toward “Hold”: 24 brokerages rate Zimmer Biomet, with 16 holds, seven buys, and one sell. Their average 12-month price target is $112.74.
• Recent quarterly results slightly exceeded expectations: earnings were $1.90 per share versus $1.88 forecast, while revenue of $2.06 billion topped estimates and rose 3.1% year over year.
• Zimmer Biomet pays a quarterly dividend of $0.24, equivalent to $0.96 annually and a 0.9% yield. The company’s stock opened at $107.47, within its 52-week range of $79.12 to $112.54.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has been assigned a consensus rating of "Hold" from the twenty-four brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, sixteen have given a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $112.74.

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada lifted their price objective on shares of Zimmer Biomet from $110.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Robert W. Baird set a $104.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. UBS Group raised their target price on Zimmer Biomet from $120.00 to $130.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Stifel Nicolaus set a $125.00 price target on Zimmer Biomet in a research report on Wednesday, November 4th. Finally, Citigroup upped their price target on Zimmer Biomet from $99.00 to $117.00 and gave the stock a "neutral" rating in a research note on Thursday, November 5th.

Zimmer Biomet Price Performance

ZBH opened at $107.47 on Wednesday. The stock has a market cap of $20.50 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 2.54 and a beta of 0.50. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $112.54. The company has a current ratio of 1.46, a quick ratio of 0.79 and a debt-to-equity ratio of 0.49. The stock has a fifty day moving average price of $95.42 and a 200 day moving average price of $92.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.88 by $0.02. The firm had revenue of $2.06 billion during the quarter, compared to analysts' expectations of $2.04 billion. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The company's revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.90 earnings per share. Analysts forecast that Zimmer Biomet will post 8.56 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet's payout ratio is 24.30%.

Insider Activity at Zimmer Biomet

In related news, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the company's stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Zimmer Biomet during the 2nd quarter valued at approximately $1,344,282,000. State Street Corp lifted its holdings in shares of Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider's stock worth $766,343,000 after buying an additional 52,044 shares during the last quarter. Primecap Management Co. CA bought a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $328,578,000. Dimensional Fund Advisors LP boosted its position in shares of Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider's stock valued at $201,082,000 after acquiring an additional 24,208 shares during the period. Finally, Bank of America Corp DE bought a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $187,480,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.